Zusammenfassung
Jährlich erkranken über 55.000 Frauen in Deutschland an Brustkrebs. In den letzten Jahren hat sich die Therapie von Patientinnen mit primärem Mammakarzinom immer mehr zu einer komplexen multimodalen Kombinationsbehandlung entwickelt. Die Behandlung sollte heute multimodal und interdisziplinär auf die einzelne Patientin abgestimmt erfolgen. Der folgende Beitrag gibt einen Überblick über die derzeitigen Standardtherapien des primären Mammakarzinoms, mit aktuellen Behandlungsempfehlungen.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Louis-Sylvestre C, Clough C, Asselain B et al (2004) Axillary Treatment in Conservative Management of Operable Breast Cancer: Dissection or Radiotherapy? Results of a Randomized Study with 15 Years of Follow-Up. J Clin Oncol 22:97–101
Jones et al (2006) J Clin Oncol 24:5381–5387
Clarke M, Collins R, Darby S et al (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 366:2087–106
Clarke M, Collins R, Darby S et al (2005) Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366:2087–106
Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B, Keshaviah A et al (2005) A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer, N Engl J Med 353:2747–57
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) Lancet 365:1687–1717
Cuzick J et al (2008) Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 12:1143–8
Jakesz R (2007) Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst 99:1845–53
Buzdar AU, Coombes RC, Goss PE et al (2008) Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer. Cancer 112:700–9
Lipton A (2008) Emerging role of bisphosphonates in the clinic – antitumor activity and prevention of metastasis to bone. Cancer Treatment Reviews 34:25–30
Winter MC (2008) Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treatment Reviews 34:453–475
Von Minckwitz G (2008) Breakthrough for neoadjuvant chemotherapy. Breast Cancer 15:27–30
Kaufmann M, von Minckwitz G, Smith R et al (2003) International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 21:2600–08
Von Minckwitz G et al (2005) In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol 16:56–63
Kaufmann M, Hortobagyi GN, Goldhirsch A et al (2006) Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 24:1940–49
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Loibl, S., Solbach, C. & Souchon, R. Primäres Mammakarzinom. best practice onkologie 4, 4–14 (2009). https://doi.org/10.1007/s11654-009-0145-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11654-009-0145-0